arrow
K

Karla V. Ballman

Alliance Statistics and Data Management Center
H指数:90
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting macrophage ferritin heavy chain mitigates ferroptosis and lung injury in experimental acute respiratory distress syndrome

靶向巨噬细胞铁蛋白重链可减轻铁死亡和实验性急性呼吸窘迫综合征中的肺损伤

2026-06-270
OAAI
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial

Tra贝替丁和低剂量伊立替康靶向EWS::FLI1在尤因肉瘤中的作用: 1/2期试验

2026-04-160
PRE
Extracellular iron and the lung microbiome in smoking and COPD
2025-11-031
PRE
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)

循环肿瘤DNA及接受CALGB 90601(Alliance)试验入组的转移性尿路上皮癌患者对顺铂为基础的化疗反应

2025-05-010
PRE
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial

pembrolizumab,放射治疗和手术与放射治疗和手术治疗肢体III期软组织肉瘤的安全性和有效性 (SU2C-SARC032): 一项开放标签,随机临床试验

LANCET
IF88.5
2024-11-010
PRE
Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution

联盟A031501:AMBASSADOR研究,评估辅助治疗中帕博利珠单抗(Pembro)在肌肉浸润性尿路上皮癌(MIUC)与观察(Obs)相比的扩展随访无病生存期(DFS)结果及转移性(met)疾病复发的分布

2024-09-010
PRE
Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort (vol 9, e181925, 2024)
2024-06-240
OA
OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)
2024-05-020
PRE
Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2-early breast cancer
2024-05-020
PRE
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
2024-03-063
PRE
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
2023-11-034
OAAI
Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer
2023-04-141
PRE